Results 71 to 80 of about 9,592 (241)

Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents [PDF]

, 2016
Association between HCV infection and diabetes has been widely postulated. Little is known about the impact of direct acting antiviral agents (DAAs) on glycemic control. Aim of our study was to evaluate the glycemic control modifications in a case series
D'Ettorre, G., LICHTNER, Miriam, MAROCCO, RAFFAELLA, MASTROIANNI, Claudio Maria, MEZZAROMA, Ivano, Passavanti, G., pavone, paolo, TIEGHI, TIZIANA, VITTOZZI, PIETRO, VULLO, Vincenzo   +9 more
core   +1 more source

The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients [PDF]

, 2023
Eman Hemeda, Howaida El Menshawy, Essam E. Hassan   +2 more
openalex   +1 more source

Pre‐Treatment Liver Stiffness Is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication

Hepatology Research, Volume 56, Issue 2, Page 161-171, February 2026.
Higher pre‐treatment liver stiffness measurement (LSM) values, rather than post‐treatment values, independently predicts hepatocellular carcinoma after hepatitis C virus eradication, underscoring the need for continued surveillance in patients with elevated baseline LSM.
Takuma Nakatsuka, Ryo Nakagomi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Kazuya Okushin, Tatsuya Minami, Masaya Sato, Koji Uchino, Yotaro Kudo, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +12 more
wiley   +1 more source

Possible acute rejection associated with the use of the new antihepatitis C virus medications

Avicenna Journal of Medicine, 2019
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant.
Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes   +4 more
doaj   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals [PDF]

, 2017
In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because ...
Caputo, Mariela, Corach, Daniel, Flichman, Diego Martin, Hulaniuk, María L., Trinks, Julieta   +4 more
core   +1 more source

Predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis C virus genotype 1

Терапевтический архив, 2017
Aim. To identify predictors for the high efficiency of short-term interferon-containing antiviral therapy (AVT) using direct-acting antivirals (DAAs) in patients with chronic hepatitis C (CHC) virus (HCV) type 1 (CHC-1). Materials and methods. A total of
K Yu Kokina, A O Bueverov, P O Bogomolov, M V Matsievich   +3 more
doaj   +1 more source

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices [PDF]

, 2014
SUMMARY. Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective,
Afdhal, N H, Castera, L, Church, D R, Dee, L, Graham, C, Jacobson, I M for the New Paradigm of HCV Therapy Meeting Participants, Litwin, A H, Mehta, S H, Muir, A, Poynard, T, Razavi, H, Schooley, R T, Sulkowski, M S, Talal, A H, Thomas, D L, Ward, J W, Zeuzem, S   +16 more
core   +1 more source

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir [PDF]

, 2023
Attiya Sabeen Rahman, Muhammad Amir, Qaiser Jamal, Mehwish Riaz, Komal Fareed, Muhammad Siddiqui   +5 more
openalex   +1 more source

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C

International Journal of Hepatology, Volume 2026, Issue 1, 2026.
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Seiichi Tawara, Asuka Watanabe, Junya Yamaguchi, Mai Omi, Tetsuro Miyazaki, Haruka Taguchi, Ryosuke Kiyota, Takuo Yamai, Shoichiro Kawai, Takuya Inoue, Takayuki Yakushijin, Dirk Uhlmann   +11 more
wiley   +1 more source